DEA Schedules Weird Benzos: Five Designer Drugs Hit Schedule I
Published Date: 3/2/2026
Rule
Summary
Starting April 1, 2026, the DEA is making it official: clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam are now permanently in Schedule I, meaning they’re considered dangerous with no accepted medical use. This affects anyone who makes, sells, or uses these drugs, bringing strict rules and penalties. The move also helps the U.S. follow international drug control agreements.
Analyzed Economic Effects
6 provisions identified: 0 benefits, 6 costs, 0 mixed.
Five designer benzodiazepines now Schedule I
Starting April 1, 2026, clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam (and their salts/isomers) are permanently placed in Schedule I of the Controlled Substances Act. That means these substances are legally treated as having high abuse potential, no accepted medical use in the United States, and are subject to Schedule I controls.
Unauthorized possession and handling unlawful
Possession or handling of clonazolam, diclazepam, etizolam, flualprazolam, or flubromazolam in any manner not authorized by the CSA is unlawful as of April 1, 2026, and may subject the person to administrative, civil, and/or criminal sanctions. Retail sales to the general public of Schedule I substances are not allowed under the CSA.
Registration required to handle these drugs
Any person who handles (manufactures, distributes, imports/exports, engages in research, conducts instructional activities or chemical analysis with, or possesses) these five substances must be registered with DEA under 21 U.S.C. 822, 823, 957, and 958 and comply with 21 CFR parts 1301 and 1312. Anyone currently handling these substances who is not registered must submit a registration application and may not continue to handle them unless DEA approves the application.
Research allowed but requires DEA permission
Placement in Schedule I does not preclude academic or scientific research, but anyone who wishes to conduct research on clonazolam, diclazepam, etizolam, flualprazolam, or flubromazolam must seek and obtain DEA permission and appropriate registration before handling them.
Schedule I regulatory controls apply (security, records)
As Schedule I substances, clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam must be handled under Schedule I security requirements, labeling and packaging rules, quotas for manufacture, biennial inventories, recordkeeping and reporting, DEA order-form requirements, and import/export controls per the CSA and implementing CFR parts (e.g., 21 CFR parts 1301, 1302, 1303, 1304, 1312, and 1317).
Surrender or transfer of existing stocks before effective date
Any person unwilling or unable to obtain a Schedule I registration must surrender or transfer all quantities of these five substances to a DEA-registered person before the effective date of the final scheduling action, and any disposal must follow 21 CFR part 1317 and applicable laws. The effective date for the permanent scheduling is April 1, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08595 — Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
The DEA is giving hexahydrocannabinol (HHC) its own official spot on the list of Schedule I drugs, making it clear that HHC is controlled separately from other similar substances. This change starts May 4, 2026, and affects anyone making, selling, or using HHC, which stays illegal under federal law. No new fees or costs are introduced, but the update helps law enforcement and businesses know exactly where HHC stands.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2026-04093 — Publication of Venezuela Sanctions Regulations Web General License 5T
The Treasury Department just made it official: starting February 3, 2026, certain deals involving Venezuela’s 2020 8.5% bond are allowed again, replacing the old rules from June 2025. This update affects anyone handling these bonds, letting them trade or finance them without breaking sanctions. It’s a big move that could open up new money flows and opportunities tied to Venezuela’s debt.
Next: 2026-04115 — Cotton Board Rules and Regulations: Adjusting Supplemental Assessment on Imports (2025 Amendments)
The USDA planned to lower the fees on imported cotton to match those on U.S. cotton, but after getting a big negative comment, they decided to cancel that change. This means importers won’t see any new fee adjustments for now, keeping things steady until further notice. The withdrawal took effect on February 26, 2026, so everyone involved should stay tuned for updates.